AMBER MCGEE: Open Payments
NPI 1326334962 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$389 in 26 payments from 12 companies in 2025. Trend: 2023 $109 · 2024 $716 · 2025 $389
Food & beverage: $389
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 13 | $113 |
| Novartis Pharmaceuticals Corporation | 2 | $49 |
| Vifor Pharma, Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Novo Nordisk Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| GENZYME CORPORATION | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
Products named: Fabhalta, Veltassa, ACTHAR, INJECTAFER, Rivfloza, LIVTENCITY, TARPEYO, FABRAZYME.
Industry payments across KS — which companies pay providers there.
